By analyzing existing fundamental indicators between Oncosec Medical and Biontech, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Biontech with a short position in Oncosec Medical. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Oncosec is to check how much profit was generated for every dollar of assets it reports. Oncosec Medical holds a negative application of assets of -61.39 pct., losing $0.61 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Oncosec Medical shows how discouraging it operates for each dollar spent on its assets.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in OncoSec Medical. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its
performance over time. Several factors influence the investment perspective on OncoSec Medical, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
Watch out for price decline
Please consider monitoring OncoSec Medical on a daily basis if you are holding a position in it. OncoSec Medical is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as OncoSec Medical stock to be traded above the $1 level to remain listed. If OncoSec Medical stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is OncoSec Medical's Liquidity
OncoSec Medical
financial leverage refers to using borrowed capital as a funding source to finance OncoSec Medical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. OncoSec Medical financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to OncoSec Medical's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of OncoSec Medical's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between OncoSec Medical's total debt and its cash.
Is OncoSec Medical valued wisely by the market?
Cash and Equivalents Breakdown
Lets now check Oncosec Medical cash and equivalents. In accordance with the recently published financial statements, Oncosec Medical has 60.33
M in Cash and Equivalents. This is 92.65% lower than that of the Healthcare sector and 86.51% lower than that of the
Biotechnology industry. The cash and equivalents for all United States stocks is 97.77% higher than that of Oncosec Medical. As for Biontech we see cash and equivalents of 914.9
M, which is 104.62% higher than that of the Biotechnology
| ONCS | 60.33 Million | 4.24 |
| Sector | 447.12 Million | 31.44 |
| BNTX | 914.9 Million | 64.32 |
Over 3 percent spike for Oncosec Medical. What does it mean for retail investors?
The value at risk is down to -8.75 as of today. Oncosec Medical exhibits very low volatility with skewness of 0.34 and kurtosis of 0.12. However, we advise investors to further study Oncosec Medical technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oncosec Medical's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oncosec Medical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Conclusion on Oncosec Medical
While some firms in the biotechnology industry are either recovering or due for a correction, Oncosec may not be as strong as the others in terms of longer-term growth potentials. To summarize, as of the 15th of October 2021, our analysis shows that Oncosec Medical responds to the market. The enterprise is
undervalued and projects
very high chance of financial distress for the next 2 years. Our primary 90 days buy-hold-sell recommendation on the enterprise is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of OncoSec Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
